NO996551D0 - Forbedrete anti-IgE-antistoffer og fremgangsmåte for forbedring av polypeptider - Google Patents

Forbedrete anti-IgE-antistoffer og fremgangsmåte for forbedring av polypeptider

Info

Publication number
NO996551D0
NO996551D0 NO996551A NO996551A NO996551D0 NO 996551 D0 NO996551 D0 NO 996551D0 NO 996551 A NO996551 A NO 996551A NO 996551 A NO996551 A NO 996551A NO 996551 D0 NO996551 D0 NO 996551D0
Authority
NO
Norway
Prior art keywords
ige antibodies
enhanced anti
enhancing polypeptides
polypeptides
enhancing
Prior art date
Application number
NO996551A
Other languages
English (en)
Other versions
NO996551L (no
NO324992B1 (no
Inventor
Henry B Lowman
Leonard G Presta
Paula M Jardieu
John Lowe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO996551D0 publication Critical patent/NO996551D0/no
Publication of NO996551L publication Critical patent/NO996551L/no
Publication of NO324992B1 publication Critical patent/NO324992B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
NO19996551A 1997-07-02 1999-12-29 Fremgangsmate for fremstilling av et modifisert polypeptid som er et anti-IgE-antistoffmolekyl, nukleinsyrer som koder for dem, preparat omfattende antistoffmolekylene og anvendelse av et antistoffmolekyl til fremstilling av et prepatat NO324992B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/887,352 US5994511A (en) 1997-07-02 1997-07-02 Anti-IgE antibodies and methods of improving polypeptides
PCT/US1998/013410 WO1999001556A2 (en) 1997-07-02 1998-06-30 IMPROVED ANTI-IgE ANTIBODIES AND METHOD OF IMPROVING POLYPEPTIDES

Publications (3)

Publication Number Publication Date
NO996551D0 true NO996551D0 (no) 1999-12-29
NO996551L NO996551L (no) 2000-03-01
NO324992B1 NO324992B1 (no) 2008-01-14

Family

ID=25390964

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19996551A NO324992B1 (no) 1997-07-02 1999-12-29 Fremgangsmate for fremstilling av et modifisert polypeptid som er et anti-IgE-antistoffmolekyl, nukleinsyrer som koder for dem, preparat omfattende antistoffmolekylene og anvendelse av et antistoffmolekyl til fremstilling av et prepatat

Country Status (29)

Country Link
US (4) US5994511A (no)
EP (1) EP0996728B1 (no)
JP (2) JP4286327B2 (no)
KR (1) KR100547538B1 (no)
CN (1) CN1260357C (no)
AR (2) AR013169A1 (no)
AT (1) ATE253116T1 (no)
AU (1) AU741115B2 (no)
BR (2) BR9810654B8 (no)
CA (1) CA2295540C (no)
CZ (1) CZ300724B6 (no)
DE (1) DE69819332T2 (no)
DK (1) DK0996728T3 (no)
ES (1) ES2210778T3 (no)
HK (1) HK1027833A1 (no)
HU (1) HU228845B1 (no)
IL (2) IL133973A0 (no)
IS (1) IS2039B (no)
NO (1) NO324992B1 (no)
NZ (1) NZ501842A (no)
PL (1) PL194562B1 (no)
PT (1) PT996728E (no)
RO (1) RO120848B1 (no)
RU (1) RU2242515C2 (no)
SK (1) SK284395B6 (no)
TR (1) TR200000206T2 (no)
TW (2) TWI233946B (no)
WO (1) WO1999001556A2 (no)
ZA (1) ZA985500B (no)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20040146507A1 (en) * 1996-11-27 2004-07-29 Genentech, Inc. Antibody mutants
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7759133B2 (en) * 1998-12-22 2010-07-20 Alk-Abello A/S Method of detecting and/or quantifying a specific IgE antibody in a liquid sample
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US20020019009A1 (en) * 1999-12-09 2002-02-14 Roggen Erwin Ludo High throughput screening (HTS) assays
DE60019458T2 (de) * 1999-12-14 2006-02-23 Thermo BioStar, Inc., Boulder Stabilisierendes verdünnungsmittel für polypeptide und antigene
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7018801B2 (en) * 2000-02-11 2006-03-28 Board Of Regents, The University Of Texas System Selection of peptides with antibody-like properties
WO2001077182A1 (fr) * 2000-04-07 2001-10-18 Matsushita Electric Industrial Co., Ltd. Complexe anticorps-porteur, procede de production, methode de controle de la reaction antigene-anticorps par ledit complexe et procede de dosage immunologique
US6951947B2 (en) * 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US7176037B2 (en) * 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU1344102A (en) 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002072141A2 (en) * 2001-03-09 2002-09-19 William Herman Targeted ligands
US6966992B2 (en) * 2001-03-19 2005-11-22 Akzo Nobel Nv Method of purification of molecules using unbranched terminal alkyldiols
WO2002102303A2 (en) * 2001-05-01 2002-12-27 Medimmune, Inc. Crystals and structure of synagis fab
WO2002089615A2 (en) * 2001-05-03 2002-11-14 Novartis Ag Anti-ige antibody to treat ocular allergies
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AU2002316230A1 (en) * 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US20030073249A1 (en) * 2001-07-07 2003-04-17 Lee Duen Allergen detection chip
JP2003137804A (ja) * 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
WO2003057881A1 (fr) * 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Procede de stabilisation d'une proteine
CN1639185A (zh) * 2002-01-03 2005-07-13 斯克里普斯研究学院 癌相关表位
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
US20050142539A1 (en) * 2002-01-14 2005-06-30 William Herman Targeted ligands
AU2003210802B2 (en) * 2002-02-05 2009-09-10 Genentech Inc. Protein purification
EP1495055B1 (en) * 2002-04-18 2013-08-14 Genencor International, Inc. Production of functional antibodies in filamentous fungi
US7569673B2 (en) * 2002-06-28 2009-08-04 The United States Of America As Represented By The Department Of Health And Human Services Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors
JP2006524036A (ja) * 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20060034833A1 (en) * 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
AU2003286003B2 (en) * 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
CN102584997A (zh) * 2002-11-08 2012-07-18 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
ES2566778T3 (es) * 2003-02-01 2016-04-15 Tanox, Inc. Anticuerpos anti-IgE de humano de alta afinidad
US20060234296A1 (en) * 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies
WO2004078965A1 (ja) * 2003-03-05 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 大腸菌における異種蛋白質の製造方法
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
KR100988129B1 (ko) * 2003-04-30 2010-10-18 쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트 인간 항인간 인터루킨-18 항체와 그 단편, 및 이들의이용방법
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
US7589181B2 (en) * 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
US20050085556A1 (en) * 2003-09-05 2005-04-21 Paul Wentworth Detection of cholesterol ozonation products
CA2537976A1 (en) 2003-09-05 2005-03-17 The Scripps Research Institute Ozonation products of cholesterol for the treatment and prevention of artherosclerosis and/or cardiovascular diseases
AU2004280593A1 (en) * 2003-10-08 2005-04-21 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
US20070212346A1 (en) 2003-10-09 2007-09-13 Tomoyuki Igawa Highly Concentrated Stabilized Igm Solution
WO2005088308A2 (en) * 2004-03-12 2005-09-22 The Scripps Research Institute Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities
EP3736295A1 (en) 2004-03-24 2020-11-11 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
EP1733234B1 (en) * 2004-04-06 2011-09-14 Mount Sinai School Of Medicine Methods of determining allergen response using microarray immunoassay techinques
US20050239757A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of macular degeneration
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US7604947B2 (en) * 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
JP4994232B2 (ja) 2004-07-23 2012-08-08 ジェネンテック， インコーポレイテッド 抗体又はその断片の結晶化
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
CA2583011A1 (en) * 2004-10-05 2006-04-20 Tanox, Inc. Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2007124933A (ru) * 2005-01-28 2009-03-10 Вайет (Us) Стабилизированные жидкие полипептидные составы
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
EP2322624B1 (en) 2005-03-25 2015-09-23 National Research Council Of Canada Method for isolation of soluble polypeptides
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
US8080249B2 (en) * 2005-06-30 2011-12-20 Risk Glifford G Methods to treating chronic obstructive pulmonary disease
DK1912675T3 (en) 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
AU2006297304B2 (en) * 2005-09-29 2012-05-17 Medimmune, Llc Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
CN101062949B (zh) * 2006-04-26 2011-07-27 上海抗体药物国家工程研究中心有限公司 重组抗人IgE单克隆抗体及其制备方法和用途
JP2009539413A (ja) 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
EP2076287A2 (en) * 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
JP2010519194A (ja) * 2007-02-15 2010-06-03 アストラゼネカ・アクチエボラーグ ＩｇＥ分子に対する結合要素
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
PA8775101A1 (es) * 2007-04-02 2008-11-19 Pfizer Anticuerpos anti-ige
LT2520590T (lt) † 2007-04-03 2018-09-10 Amgen Research (Munich) Gmbh Susijusioms rūšims specifinis rišantis domenas
MX2009010611A (es) * 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
CA2682738A1 (en) * 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
CA2683568A1 (en) * 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
RS53850B2 (sr) 2007-10-30 2018-07-31 Genentech Inc Pročišćavanje antitela hromatografijom izmene katjona
JP5373823B2 (ja) * 2008-01-29 2013-12-18 アブリンクス エン．ヴェー． タンパク質及びポリペプチドを安定化する方法
ES2368700T3 (es) * 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
IT1391559B1 (it) * 2008-09-01 2012-01-11 Lofarma Spa Allergoidi derivati da allergeni
EP2853545B8 (en) 2008-09-17 2023-04-05 Xencor, Inc. Antibody specific for IgE
CA2739352C (en) * 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
KR101581986B1 (ko) 2008-10-29 2016-01-04 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
EP2358390A1 (en) * 2008-11-13 2011-08-24 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic combination therapies and uses thereof
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
CN105037535A (zh) 2008-12-16 2015-11-11 Emd密理博公司 搅拌槽反应器及方法
EP2403874A1 (en) * 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
EP2494356B1 (en) 2009-10-26 2017-03-15 Genentech, Inc. Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
SG10201502587SA (en) 2010-03-01 2015-06-29 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
PL2550018T3 (pl) 2010-03-22 2019-08-30 F.Hoffmann-La Roche Ag Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko
BR112012025645A2 (pt) 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
EP2571903B1 (en) 2010-05-17 2019-09-04 EMD Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
EP3351559A3 (en) 2010-11-08 2018-10-31 F. Hoffmann-La Roche AG Subcutaneously administered anti-il-6 receptor antibody
US9170249B2 (en) 2011-03-12 2015-10-27 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing N-glycans in glycoprotein products
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
WO2013116287A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
WO2013120973A1 (en) * 2012-02-15 2013-08-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of producing high-affinity antibodies
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
BR112014028600B1 (pt) 2012-05-18 2022-11-22 Genentech, Inc Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
WO2013181577A2 (en) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
EP2856159A4 (en) 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc METHODS RELATING TO DENOSUMAB
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014041544A1 (en) * 2012-09-12 2014-03-20 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2014149067A1 (en) 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
PE20160724A1 (es) 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t
KR20160086360A (ko) 2013-11-13 2016-07-19 제넨테크, 인크. 보조식 수동 주사기 기기 및 방법
BR112016025312A2 (pt) * 2014-05-01 2017-10-17 Genentech Inc variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
CA2943588C (en) * 2014-06-17 2019-04-30 Academia Sinica Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells
ES2825574T3 (es) 2014-07-09 2021-05-17 Hoffmann La Roche Ajuste del pH para mejorar la recuperación por descongelación de bancos de células
EP3194449A1 (en) 2014-07-24 2017-07-26 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
WO2016164920A1 (en) 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
EP3368090A1 (en) * 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2018015881A1 (en) 2016-07-18 2018-01-25 Ramot At Tel-Aviv University Ltd. Modular platform for targeted therapeutics
EP3538558A4 (en) * 2016-11-09 2020-07-15 North Carolina State University TREATMENT OF ALLERGIC DISEASES WITH A CHIMERAL PROTEIN
JP2020503316A (ja) 2016-12-22 2020-01-30 ジェネンテック， インコーポレイテッド 凍結乾燥ポリペプチドの再構成時間を低減するための方法及び製剤
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN117820498A (zh) * 2017-08-10 2024-04-05 盖立复诊断解决方案公司 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒
KR102652133B1 (ko) * 2018-02-01 2024-03-29 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 IL-4Rα 항체 및 그 용도
SG11202007564VA (en) 2018-02-09 2020-09-29 Genentech Inc Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
AU2021306786A1 (en) * 2020-07-10 2023-02-16 Jiangxi Jemincare Group Co., Ltd. Anti-IgE engineered antibody and application thereof
CN111879923A (zh) * 2020-08-06 2020-11-03 深圳科隆生物新材料有限公司 一种可消除hama效应的试剂盒

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6031471B2 (ja) * 1978-07-21 1985-07-22 協和醗酵工業株式会社 グリセロ−ル酸化酵素およびその製法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
ES2113940T3 (es) * 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2206447T3 (es) * 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
CA2113813C (en) * 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US6329509B1 (en) * 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
JPH07501451A (ja) * 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE228536T1 (de) 1993-03-11 2002-12-15 Tanox Biosystems Inc Antigene epitope von ige repräsentierenden peptiden auf der b-zell-oberfläche aber nicht auf oberflächen von basophilen
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5561053A (en) 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CZ45498A3 (cs) * 1995-08-17 1999-01-13 Protein Design Labs, Inc. Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides

Also Published As

Publication number Publication date
IS2039B (is) 2005-08-15
JP4286327B2 (ja) 2009-06-24
HK1027833A1 (en) 2001-01-23
EP0996728B1 (en) 2003-10-29
TW570976B (en) 2004-01-11
KR100547538B1 (ko) 2006-01-31
IS5321A (is) 1999-12-23
US6761889B2 (en) 2004-07-13
ES2210778T3 (es) 2004-07-01
EP0996728A2 (en) 2000-05-03
PL338030A1 (en) 2000-09-25
RO120848B1 (ro) 2006-08-30
HUP0002474A3 (en) 2003-03-28
JP2002510211A (ja) 2002-04-02
BR9810654B1 (pt) 2013-01-08
TR200000206T2 (tr) 2000-07-21
SK284395B6 (sk) 2005-03-04
CA2295540C (en) 2011-01-25
DE69819332T2 (de) 2004-07-15
DK0996728T3 (da) 2004-02-23
HU228845B1 (en) 2013-06-28
AU8270198A (en) 1999-01-25
IL133973A0 (en) 2001-04-30
US20030149244A1 (en) 2003-08-07
NO996551L (no) 2000-03-01
IL133973A (en) 2006-12-10
CA2295540A1 (en) 1999-01-14
CZ300724B6 (cs) 2009-07-29
DE69819332D1 (de) 2003-12-04
HUP0002474A2 (hu) 2000-10-28
TWI233946B (en) 2005-06-11
AR060038A2 (es) 2008-05-21
ZA985500B (en) 1999-12-24
JP2009055902A (ja) 2009-03-19
US20020054878A1 (en) 2002-05-09
NZ501842A (en) 2002-02-01
PT996728E (pt) 2004-03-31
ATE253116T1 (de) 2003-11-15
CN1268176A (zh) 2000-09-27
PL194562B1 (pl) 2007-06-29
RU2242515C2 (ru) 2004-12-20
AR013169A1 (es) 2000-12-13
US6290957B1 (en) 2001-09-18
US6682735B2 (en) 2004-01-27
BR9810654B8 (pt) 2013-02-19
US5994511A (en) 1999-11-30
NO324992B1 (no) 2008-01-14
WO1999001556A2 (en) 1999-01-14
AU741115B2 (en) 2001-11-22
JP4371248B2 (ja) 2009-11-25
BRPI9810654C1 (pt) 2021-05-25
SK187599A3 (en) 2001-08-06
BR9810654A (pt) 2005-10-04
WO1999001556A3 (en) 1999-04-22
KR20010014422A (ko) 2001-02-26
CN1260357C (zh) 2006-06-21
CZ473599A3 (cs) 2000-06-14

Similar Documents

Publication Publication Date Title
NO996551D0 (no) Forbedrete anti-IgE-antistoffer og fremgangsmåte for forbedring av polypeptider
NO974939D0 (no) Protein-adhesiv-bindemiddel og fremgangsmåte for dannelse av et protein-adhesiv-bindemiddel
NO20071415L (no) OB-fusjonsproteinpreparater og fremgangsmater
NO963371D0 (no) Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det
DK0825946T3 (da) Fremgangsmåde til lastning og behandling af hydrocarboner
NO985278D0 (no) Elektromagnetiske-til-akustiske og akustiske-til-elektro-magnetiske forsterkere og fremgangsmÕter for bruk av disse
DE69841090D1 (de) Ladungsregelungsverfahren und -vorrichtung
NO962346D0 (no) Humaniserte antistoffer og anvendelser derav
IS5525A (is) Innúðabúnaður og aðferð
IL136335A0 (en) Monoclonal human natural antibodies
NO976122L (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
EP0870826A4 (en) NEW PROTEINS AND MONOCLONAL ANTIBODIES AGAINST THESE
DK0892035T3 (da) Flerfaseemulsion og fremgangsmåde til fremstilling heraf
NO972578L (no) FremgangsmÕte og anordning for forsegling
NO20002072L (no) FremgangsmÕte og anordning for frakt av superfrosne materialer
EE9900598A (et) Maksemeetod ja -süsteem
NO980566D0 (no) Allergen-XCD32 fusjonsproteiner
NO971448D0 (no) Anti-Fas rekombinante antistoffer og DNA derfor
BR9606978A (pt) Anticorpos monoclonais antiidiótipos (ab2) e usos dos mesmos
DK1003682T3 (da) Stuveelement og fremgangsmåde til stuvning af beholdere
DK1020524T3 (da) Mutant bioluminescerende protein og fremgangsmåde til fremstilling af det mutante bioluminescerende protein
DK0966387T3 (da) Fremgangsmåde til infrarød sløring samt infrarød reflektor
DK0780388T3 (da) 5HT1Dalfa og 5HT2A ligander
GB9718911D0 (en) Monoclonal antibodies
EP0984065A4 (en) MODIFIED PROTEINANTIGENT FROM TREPONEMA PALLADIUM.

Legal Events

Date Code Title Description
MK1K Patent expired